Cart
sales@molnova.com
30-Hydroxygambogic acid
CAS No. 881027-36-7
30-Hydroxygambogic acid( —— )
Catalog No. M31208 CAS No. 881027-36-7
30-Hydroxygambogic acid exhibits significant cytotoxicities against the human leukemia K562/S and the corresponding doxorubicin-resistant K562/R cell lines.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name30-Hydroxygambogic acid
-
NoteResearch use only, not for human use.
-
Brief Description30-Hydroxygambogic acid exhibits significant cytotoxicities against the human leukemia K562/S and the corresponding doxorubicin-resistant K562/R cell lines.
-
Description30-Hydroxygambogic acid exhibits significant cytotoxicities against the human leukemia K562/S and the corresponding doxorubicin-resistant K562/R cell lines.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number881027-36-7
-
Formula Weight644.8
-
Molecular FormulaC38H44O9
-
Purity>98% (HPLC)
-
SolubilityDMSO, Pyridine, Methanol, Ethanol, etc.
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Chem Biodivers. 2006 Jan;3(1):101-5.
molnova catalog
related products
-
Cyclo(L-Phe-L-Pro)
Cyclo(L-Phe-L-Pro) shows broad-spectrum antibacterial and antifungal activities. Cyclo(L-Phe-L-Pro) exhibits activity against methicillin-resistant S. aureus and Enterococcus raffinosus.
-
Martynoside
Martynoside is a natural selective estrogen receptor modulator, which has antioxidative, anti-muscle fatigue, anticancer and antimetastatic activities.
-
MSC2504877
MSC2504877 is an inhibitor of tankyrase and enhances the effects of clinical CDK4/6 inhibitors. MSC2504877 suppresses the upregulation of Cyclin D2 and Cyclin E2 caused by palbociclib and enhances the suppression of phospho-Rb.
